Hsiang-Fong Kao1,2,3, Pei-Jen Lou4. 1. Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan. 2. Department of Medical Oncology, National Taiwan University Cancer Center, Taipei City, Taiwan. 3. Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan. 4. Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei City, Taiwan.
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) can reinvigorate T cells and activate the immune system to eliminate cancer cells. Head and neck squamous cell carcinoma (HNSCC) is a malignancy with a poor prognosis. The roles of ICIs for HNSCC treatments are emerging. METHOD: We reviewed the study results of Programmed-Death 1 (PD-1) and PD-ligand-1 (PD-L1) monoclonal antibodies for HNSCC. The ongoing trials of anti-PD-1 and anti-PD-L1 were also reviewed. RESULTS: Nivolumab showed a significant overall survival benefit in platinum-refractory HNSCC patients. For platinum-sensitive or first-line patients, pembrolizumab monotherapy (patients with PD-L1 Combined Positive Score ≥ 20) or pembrolizumab-platinum-fluorouracil improved overall survival vs the EXTREME (cetuximab-platinum-fluorouracil). Many HNSCC studies have combined anti-PD1/PD-L1 therapy with various anticancer agents or radiotherapy to improve treatment efficacy. CONCLUSION: ICIs demonstrate their efficacies for R/M HNSCC patients. The incorporation of ICIs showed a great impact on the treatment landscape of HNSCC.
BACKGROUND: Immune checkpoint inhibitors (ICIs) can reinvigorate T cells and activate the immune system to eliminate cancer cells. Head and neck squamous cell carcinoma (HNSCC) is a malignancy with a poor prognosis. The roles of ICIs for HNSCC treatments are emerging. METHOD: We reviewed the study results of Programmed-Death 1 (PD-1) and PD-ligand-1 (PD-L1) monoclonal antibodies for HNSCC. The ongoing trials of anti-PD-1 and anti-PD-L1 were also reviewed. RESULTS: Nivolumab showed a significant overall survival benefit in platinum-refractory HNSCC patients. For platinum-sensitive or first-line patients, pembrolizumab monotherapy (patients with PD-L1 Combined Positive Score ≥ 20) or pembrolizumab-platinum-fluorouracil improved overall survival vs the EXTREME (cetuximab-platinum-fluorouracil). Many HNSCC studies have combined anti-PD1/PD-L1 therapy with various anticancer agents or radiotherapy to improve treatment efficacy. CONCLUSION: ICIs demonstrate their efficacies for R/M HNSCC patients. The incorporation of ICIs showed a great impact on the treatment landscape of HNSCC.
Authors: Marcus A Florez; Jan O Kemnade; Nan Chen; Wendy Du; Anita L Sabichi; Daniel Y Wang; Quillan Huang; Courtney N Miller-Chism; Aparna Jotwani; Albert C Chen; David Hernandez; Vlad C Sandulache Journal: Cancer Res Commun Date: 2022-07-26
Authors: Sehrish Javaid; Antje Schaefer; Craig M Goodwin; Victoria V Nguyen; Frances L Massey; Mariaelena Pierobon; Da'Jhnae Gambrell-Sanders; Andrew M Waters; Kathryn N Lambert; J Nathaniel Diehl; G Aaron Hobbs; Kris C Wood; Emanuel F Petricoin; Channing J Der; Adrienne D Cox Journal: Mol Cancer Ther Date: 2022-05-04 Impact factor: 6.009